Dr. Lal PathLabs Limited announced its audited financial results for the quarter and year ended March 31, 2026, following the Board of Directors meeting held on April 30, 2026. The company reported mixed quarterly performance with revenue growth but profit decline in Q4FY26. For the full fiscal year, the company maintained strong performance with consolidated revenue from operations of INR 27,629 million and consolidated profit of INR 5,098 million, representing growth from the previous year.

Q4FY26 Performance Analysis

The company's Q4FY26 results showed contrasting trends with revenue growth but profit compression. Consolidated net profit declined to INR 1.30 billion compared to INR 1.55 billion in the same quarter last year. However, revenue demonstrated strong growth, reaching INR 7.00 billion versus INR 6.03 billion in Q4FY25. EBITDA performance showed improvement, rising to INR 1.87 billion from INR 1.69 billion year-on-year, though EBITDA margin compressed to 26.60% from 28.05% in the previous year.

Full Year Financial Performance

For the complete financial year FY26, Dr. Lal PathLabs delivered robust performance with consolidated revenue from operations reaching INR 27,629 million, representing growth from INR 24,614 million in the previous year. Consolidated profit for the year stood at INR 5,098 million with earnings per share (basic) of INR 30.24. The standalone results showed revenue from operations of INR 26,476 million for FY26, with profit increasing to INR 5,082 million compared to INR 4,973 million in the previous year.

Dividend and Strategic Initiatives

The Board of Directors recommended a final dividend of INR 4.00 per equity share for FY26, subject to shareholder approval at the Annual General Meeting. The record date for dividend payment has been fixed as June 26, 2026. Including the final dividend, the total dividend for FY26 amounts to INR 20.50 per equity share, comprising interim dividends paid during the year.

The Board approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited for a cash consideration not exceeding INR 20 crores. The company also approved the incorporation of a wholly owned subsidiary in Dubai, United Arab Emirates, named Dr. Lal PathLabs FZCO, subject to necessary regulatory approvals.

Corporate Governance and Management

The Board re-appointed (Hony) Brig. Dr. Arvind Lal, Padma Shri, as Executive Chairman and Whole-Time Director for five years commencing from April 1, 2027, subject to shareholder approval. Mr. Rajit Mehta was re-appointed as Non-Executive Independent Director for five years from July 27, 2026. The company also designated Dr. Reena Nakra and Dr. Saloni Khera as Senior Management Personnel effective April 30, 2026. The 32nd Annual General Meeting has been convened on July 25, 2026, through video conferencing.

Regulatory Compliance and Disclosure

Pursuant to Regulation 30 and 46(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has made available the audio recording of its earnings conference call with investors and analysts for Q4 & FY26 held on April 30, 2026. The recording is accessible on the company's official website at https://www.lalpathlabs.com/investors/investors-inside/quarterly-result , ensuring transparency and compliance with regulatory disclosure requirements.

In compliance with Regulation 30 and 47 of SEBI regulations, the company published newspaper advertisements of its financial results for the quarter and year ended March 31, 2026, in Financial Express and Jansatta on May 01, 2026. The advertisements were duly filed with the National Stock Exchange of India Limited and BSE Limited as per regulatory requirements.

Dr. Lal Path Labs Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory requirements under SEBI depositories regulations for the quarter ended March 31, 2026.

Regulatory Compliance Filing

The diagnostic services company filed its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 on April 09, 2026. Company Secretary and Compliance Officer Vinay Gujral submitted the documentation to both the National Stock Exchange of India Limited and BSE Limited.

RTA Confirmation Certificate

MUFG Intime India Private Limited, formerly Link Intime India Private Limited, serves as the company's Registrar & Share Transfer Agent. The RTA issued its confirmation certificate on April 6, 2026, which was subsequently enclosed with Dr. Lal PathLabs' regulatory filing.

Swapan Kumar Naskar, Associate Vice President & Head of the Delhi Branch at MUFG Intime India, confirmed that during the quarter ended March 31, 2026, the RTA did not receive any demat requests for processing. The certificate specifically noted that Dr. Lal PathLabs does not maintain any physical shares.

Corporate Structure Details

The filing included standard corporate identification details for both exchanges. Dr. Lal PathLabs trades on NSE under the symbol LALPATHLAB and on BSE with scrip code 539524. MUFG Intime India Private Limited operates under CIN U67190MH1999PTC118368 and functions as part of MUFG Corporate Markets, a division of MUFG Pension & Market Services.

This quarterly compliance filing represents routine regulatory adherence, ensuring transparency in share transfer and dematerialization processes as mandated by SEBI regulations for listed companies.